TABLE OF CONTENTS
1 INTRODUCTION 30
1.1 OBJECTIVES OF THE STUDY 30
1.2 MARKET DEFINITION 30
1.3 OVERVIEW OF ASIA-PACIFIC BLOOD SCREENING MARKET 30
1.4 CURRENCY AND PRICING 31
1.5 LIMITATION 32
1.6 MARKETS COVERED 32
2 MARKET SEGMENTATION 36
2.1 MARKETS COVERED 36
2.2 GEOGRAPHIC SCOPE 37
2.3 YEARS CONSIDERED FOR THE STUDY 38
2.4 CURRENCY AND PRICING 38
2.5 RESEARCH METHODOLOGY 39
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 42
2.7 DBMR MARKET POSITION GRID 43
2.8 THE CATEGORY VS TIME GRID 44
2.9 THE CATEGORY VS TIME GRID 45
2.10 DBMR MARKET CHALLENGE MATRIX 46
2.11 SECONDARY SOURCES 47
2.12 ASSUMPTIONS 47
3 MARKET OVERVIEW 48
3.1 DRIVERS 50
3.1.1 RISE IN THE DEMAND OF BLOOD DONATIONS AND BLOOD DONORS 50
3.1.2 RISING PREVALENCE IN NUMBER OF DISEASES 50
3.1.3 RISING NUMBER OF INITIATIVES BY VARIOUS GOVERNMENTS AND GOVERNMENT ASSOCIATIONS 51
3.2 RESTRAINTS 52
3.2.1 LACK OF USING NAT TECHNLOGY IN EMERGING COUNTRIES 52
3.2.2 HIGH COST OF TECHNOLOGY AND INSTRUMENTS 52
3.2.3 EMERGING ALTERNATIVE TECHNOLOGIES 53
3.3 OPPORTUNITIES 54
3.3.1 INCREASING MICROBIOLOGY SCREENING & MULTIPLEXING 54
3.4 CHALLENGES 55
3.4.1 REDUCTION IN PRICE FOR TECHNOLOGY AND INSTRUMENT 55
4 EXECUTIVE SUMMARY 56
5 PREMIUM INSIGHTS 59
6 ASIA-PACIFIC BLOOD SCREENING MARKET, BY PRODUCTS & SERVICES 62
6.1 OVERVIEW 63
6.2 REAGENTS & KITS 65
6.2.1 ELISA REAGENTS & KITS 67
6.2.1.1 IMMUNOSORBENTS 68
6.2.1.2 CONJUGATES 68
6.2.1.3 SUBSTRATES 68
6.2.1.4 CONTROLS 68
6.2.1.5 SAMPLE DILUENTS AND WASH SOLUTIONS 68
6.2.2 NAT REAGENTS & KITS 68
6.2.2.1 PROBES AND PRIMERS 69
6.2.2.2 ENZYMES AND POLYMERASES 69
6.2.2.3 LABELING AND DETECTION REAGENTS 69
6.2.2.4 STANDARDS AND CONTROLS 69
6.2.2.5 BUFFERS, NUCLEOTIDES AND SOLUTIONS 69
6.3 INSTRUMENTS 70
6.3.1.1 INSTRUMENTS, PRODUCT TYPE 71
6.3.1.1.1 SEMI AUTOMATED 71
6.3.1.1.2 AUTOMATED 71
6.3.1.2 INSTRUMENTS, PURCHASE TYPE 71
6.3.1.2.1 OUTRIGHT PURCHASE 71
6.3.1.2.2 RENTAL 71
6.4 SOFTWARE & SERVICES 72
7 ASIA-PACIFIC BLOOD SCREENING MARKET, BY TECHNOLOGY 73
7.1 OVERVIEW 74
7.2 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) 76
7.2.1 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), BY PLATFORM 78
7.2.1.1 COLORIMETRIC IMMUNOASSAY (CI) 78
7.2.1.2 CHEMILUMINESCENCE IMMUNOASSAY (CLIA) 78
7.2.1.3 FLUORESCENCE IMMUNOASSAY (FIA) 78
7.2.2 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), BY GENERATIONS 78
7.2.2.1 FIRST-GENERATION ELISA 78
7.2.2.2 SECOND-GENERATION ELISA 78
7.2.2.3 THIRD-GENERATION ELISA 78
7.2.2.4 FOURTH-GENERATION ELISA 78
7.3 RAPID TESTS 79
7.4 NEXT-GENERATION SEQUENCING (NGS) 80
7.5 NUCLEIC ACID TEST 81
7.5.1 REAL-TIME POLYMERASE CHAIN REACTION (PCR) 82
7.5.2 TRANSCRIPTION-MEDIATED AMPLIFICATION (TMA) 82
7.6 WESTERN BLOT ASSAY 83
7.7 OTHERS 84
8 ASIA-PACIFIC BLOOD SCREENING MARKET, BY DISEASE TYPE 85
8.1 OVERVIEW 86
8.2 ONCOLOGY 88
8.3 DIABETES MELLITUS 89
8.4 COLD & FLU 90
8.5 CHOLESTEROL 91
8.6 INFECTIOUS DISEASES 92
8.7 RESPIRATORY DISEASES 93
8.8 HIV/AIDS 94
8.9 OTHERS 95
9 ASIA-PACIFIC BLOOD SCREENING MARKET, BY END USER 96
9.1 OVERVIEW 97
9.2 DIAGNOSTIC CENTERS 99
9.3 BLOOD BANK 100
9.4 HOSPITALS 101
9.5 CLINICS 102
9.6 AMBULATORY SURGICAL CENTERS 103
10 ASIA-PACIFIC BLOOD SCREENING MARKET, BY GEOGRAPHY 104
10.1 ASIA-PACIFIC 104
10.1.1 CHINA 115
10.1.2 JAPAN 122
10.1.3 SOUTH KOREA 129
10.1.4 INDIA 136
10.1.5 SINGAPORE 143
10.1.6 AUSTRALIA 150
10.1.7 THAILAND 157
10.1.8 MALAYSIA 164
10.1.9 INDONESIA 171
10.1.10 PHILIPPINES 178
10.1.11 REST OF ASIA-PACIFIC 185
11 ASIA-PACIFIC BLOOD SCREENING MARKET, COMPANY LANDSCAPE 186
11.1 COMPANY SHARE ANALYSIS; ASIA-PACIFIC 186
12 COMPANY PROFILES 187
12.1 F. HOFFMANN-LA ROCHE LTD 187
12.1.1 COMPANY OVERVIEW 187
12.1.2 REVENUEANALYSIS 187
12.1.3 COMPANY SHARE ANALYSIS 188
12.1.4 PRODUCT PORTFOLIO 188
12.1.5 RECENT DEVELOPMENT 189
12.2 ABBOTT 190
12.2.1 COMPANY OVERVIEW 190
12.2.2 REVENUE ANALYSIS 190
12.2.3 COMPANY SHAREV ANALYSIS 191
12.2.4 PRODUCT PORTFOLIO 191
12.2.5 RECENT DEVELOPMENT 192
12.3 THERMO FISHER SCIENTIFIC INC. 193
12.3.1 COMPANY OVERVIEW 193
12.3.2 REVENUE ANALYSIS 193
12.3.3 COMPANY SHAREV ANALYSIS 194
12.3.4 PRODUCT PORTFOLIO 194
12.3.5 RECENT DEVELOPMENTS 195
12.4 SIEMENS AG 196
12.4.1 COMPANY OVERVIEW 196
12.4.2 REVENUE ANALYSIS 196
12.4.3 COMPANY SHAREV ANALYSIS 197
12.4.4 PRODUCT PORTFOLIO 197
12.4.5 RECENT DEVELOPMENTS 199
12.5 BIO-RAD LABORATORIES, INC. 200
12.5.1 1.3.1COMPANY OVERVIEW 200
12.5.2 REVENUE ANALYSIS 200
12.5.3 COMPANY SHAREV ANALYSIS 201
12.5.4 PRODUCT PORTFOLIO 201
12.5.5 RECENT DEVELOPMENTS 203
12.6 BD 204
12.6.1 COMPANY OVERVIEW 204
12.6.2 REVENUE ANALYSIS 204
12.6.3 PRODUCT PORTFOLIO 205
12.6.4 RECENT DEVELOPMENTS 205
12.7 BECKMAN COULTER, INC. 206
12.7.1 COMPANY OVERVIEW 206
12.7.2 GEOGRAPHICPRESENCE 206
12.7.3 PODUCT PORTFOLIO 207
12.7.4 RECENET DEVELOPEMENTS 208
12.8 BIOM?RIEUX SA 209
12.8.1 COMPANY OVERVIEW 209
12.8.2 REVENUE ANALYSIS 209
12.8.3 PRODUCT PORTFOLIO 210
12.8.4 RECENT DEVELOPMENT 211
12.9 CEPHEID (A SUBSIDIARY OF DANAHER CORPORATION) 212
12.9.1 COMPANY OVERVIEW 212
12.9.2 GEOGRAPHIC PRESENCE 212
12.9.3 PRODUCT PORTFOLIO 213
12.9.4 RECENT DEVELOPMENT 214
12.10 ENZO BIOCHEM INC. 215
12.10.1 COMPANY OVERVIEW 215
12.10.2 REVENUE ANALYSIS 215
12.10.3 PRODUCT PORTFOLIO 216
12.10.4 RECENT DEVELOPMENTS 217
12.11 GRIFOLS INTERNATIONAL, S.A. 218
12.11.1 COMPANY OVERVIEW 218
12.11.2 REVENUE ANALYSIS 218
12.11.3 PRODUCT PORTFOLIO 219
12.11.4 RECENT DEVELOPMENTS 220
12.12 HOLOGIC INC. 221
12.12.1 COMPANY OVERVIEW 221
12.12.2 REVENUE ANALYSIS 221
12.12.3 PRODUCT PORTFOLIO 222
12.12.4 RECENT DEVELOPMENTS 222
12.13 IMMUCOR, INC. 223
12.13.1 COMPANY OVERVIEW 223
12.13.2 GEOGRAPHIC PRESENCE; 223
12.13.3 PRODUCT PORTFOLIO 224
12.13.4 RECENT DEVELOPMENTS 225
12.14 MERIDIAN BIOSCIENCE, INC. 226
12.14.1 COMPANY OVERVIEW 226
12.14.2 REVENUE ANALYSIS 226
12.14.3 PRODUCT PORTFOLIO 227
12.14.4 RECENT DEVELOPMENTS 228
12.15 ORTHO CLINICAL DIAGNOSTICS 229
12.15.1 COMPANY OVERVIEW 229
12.15.2 GEOGRAPHIC PRESENCE 229
12.15.3 PRODUCT PORTFOLIO 230
12.15.4 RECENT DEVELOPMENTS 231
13 RELATED REPORTS 232